Canada Companion Animal Healthcare Market, by Pharmaceuticals, 2018-2027

Growth Outlook

• The 2027 portion of the Canada Companion Animal Healthcare Market, by Pharmaceuticals, 2018 market is on a steady long-term growth path. Segment value stands at roughly USD 307 Mn in 2026 and is projected to reach USD 334 Mn by 2027 — a gain of about 9% over the forecast period, translating to a CAGR in the high single digits.
• Of the 4 groups compared here, Anti-Infectives is out front by 2027 at 109. 56M USD — 33% of the group total.
• What the regional split looks like (2026): Anti-Infectives leads, holding roughly 33% of segment value — the single largest regional share. Others is the second-largest contributor. Antibiotics and Anti-Inflammatories make up the remainder, in descending order.
• By 2027, Anti-Infectives alone is expected to reach USD 110 Mn, with Others at USD 85 Mn.

Market Dynamics

Of the 4 groups compared here, Anti-Infectives is out front by 2027 at 109.56M USD — 33% of the group total.

Second place: Others, 85.45M USD, trailing Anti-Infectives by 22%.

Anti-Infectives: up 96% over the period, 55.94M USD to 109.56M USD.

Others climbs from 41.47M USD (2018) to 85.45M USD (2027), a 106% gain.

Antibiotics: 41.78M USD to 80.73M USD, 93% higher by 2027.

Anti-Inflammatories: 26.98M USD in 2018 to 58.64M USD by 2027, up 117%.

By rate of change, not size, Anti-Inflammatories is the standout — 117% growth, faster than the rest of the group.

Add every series together and the total reaches 334.38M USD by 2027, 101% above the 2018 combined figure of 166.17M USD.

Reading A Multi-Series Chart

With 4 series on one chart, the shape that matters is how the ranking shifts over time, not just where each line starts or ends.

Size and growth rate are two different questions here — a series can be small in absolute terms and still be growing the fastest of the group. Check both before drawing a conclusion.

Use this chart to size the Canada Companion Animal Healthcare market and to compare how fast it is expected to grow against adjacent markets — it works best as an input to a market-entry or investment decision, not as a standalone verdict.

The numbers here come from a market sizing model: historical revenue estimates up to the 2018 base year, then forecasts through 2027 using growth-rate assumptions for each segment. The underlying report explains the methodology in detail.